Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.71 |
| ▸ | CDC25A | P30304 | 1/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.71 |
| ▸ | AKT1 | P31749 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.71 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.58 |
| ▸ | FABP3 | P05413 | 1/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GMNN | O75496 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240744 | 1.00 | LMNA (0.71) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL29935531 | 0.93 | SMN1; SMN2 (0.63) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL26018724 | 0.88 | FABP3 (0.70) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL25665820 | 0.88 | FABP3 (0.70) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL14758262 | 0.88 | FABP3 (0.70) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL26061597 | 0.88 | FABP3 (0.70) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL10937572 | 0.86 | SMN1; SMN2 (0.64) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL7720034 | 0.86 | SMN1; SMN2 (0.64) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL1643920 | 0.86 | LMNA (0.66) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL5475887 | 0.86 | LMNA (0.66) | LMNAESR1ADORA3CDC25AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943602-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG, INC. (US) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243430-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, LIPC, FABP6 | LMNA 1669/4885ESR1 2850/4885ADORA3 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.